The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome

NCT ID: NCT03473951

Last Updated: 2020-06-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

18000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-26

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperuricemia is associated with the prevalence of metabolic syndrome and cardiovascular risks in diverse of the population. Whether the dose-response effects on the prevalence of metabolic syndrome and cardiometabolic risks is unclear. The present study is conducted to investigate the relationship between serum uric acid and the prevalence metabolic syndrome and left ventricular hypertrophy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Apparently healthy individuals with an estimated screening number of approximately twenty-thousand individuals undergo an annual health exam in the investigators' hospital. The routine exam includes measurements of body height, body weight, blood pressure, visual and acoustic acuity, physical examinations, basic blood tests, urine analyses, chest radiography, and electrocardiography. The blood tests were performed after individuals fasted for at least eight hours. Individuals with any abnormal results underwent a clinical examination at an outpatient department for safety issues, ensuring the accuracy of the data. All data were registered prospectively. The investigators retrospectively collected data from the annual exam.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperuricemia Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyperuricemia

Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women

Hyperuricemia

Intervention Type DIAGNOSTIC_TEST

Hyperuricemia vs. normouricemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperuricemia

Hyperuricemia vs. normouricemia

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with ages of 20-65 years underwent the annual health exam at the investigators' hospital.

Exclusion Criteria

* The individual had no data to define metabolic syndrome, including waist circumference, office blood pressure, serum uric acid, triglyceride, high-density lipoprotein cholesterol, fasting glucose.
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Defense Medical Center, Taiwan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cheng-Wei Liu

Cardiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tri-service General Hospital, songshan branch

Taipei, Songshan Dist., Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Liu

Role: CONTACT

+886-2-27642151 ext. 671401

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Liu, MD

Role: primary

+886-910682383

References

Explore related publications, articles, or registry entries linked to this study.

Tu CM, Wei TE, Tseng GS, Chen CC, Liu CW. Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals. Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3142-3151. doi: 10.1016/j.numecd.2021.07.008. Epub 2021 Jul 24.

Reference Type DERIVED
PMID: 34518090 (View on PubMed)

Liu CW, Ke SR, Tseng GS, Wu YW, Hwang JJ. Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines. Nutr Metab Cardiovasc Dis. 2021 Apr 9;31(4):1209-1218. doi: 10.1016/j.numecd.2021.01.003. Epub 2021 Jan 12.

Reference Type DERIVED
PMID: 33618920 (View on PubMed)

Liu CW, Chen KH, Tseng CK, Chang WC, Wu YW, Hwang JJ. The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. Nutr Metab Cardiovasc Dis. 2019 Jan;29(1):30-38. doi: 10.1016/j.numecd.2018.10.001. Epub 2018 Oct 16.

Reference Type DERIVED
PMID: 30545672 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2-106-05-148

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gout Dose Response Study
NCT00955981 COMPLETED PHASE2
The Diet Gout Trial
NCT03569020 COMPLETED NA